➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
McKesson
Johnson and Johnson
Mallinckrodt
Colorcon
Harvard Business School

Last Updated: July 28, 2021

DrugPatentWatch Database Preview

Details for Patent: 8,946,262


Email this page to a colleague

« Back to Dashboard

Which drugs does patent 8,946,262 protect, and when does it expire?

Patent 8,946,262 protects ENTEREG and is included in one NDA.

This patent has one patent family member in one country.

Summary for Patent: 8,946,262
Title:Methods of preventing and treating gastrointestinal dysfunction
Abstract: Methods of preventing and treating gastrointestinal dysfunction, particularly postoperative ileus and post-partum ileus, in a patient undergoing surgery or other biological stress by administering 4-aryl-piperidine derivatives are disclosed.
Inventor(s): Christ; David D (Newark, DE), Wallin; Bruce A (Haverford, PA), Garver; Deanne D (Downingtown, PA), Schmidt; William K (Davis, CA), Jackson; David (Cape Coral, FL)
Assignee: Adolor Corporation (Lexington, MA)
Application Number:10/999,054
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,946,262

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Cubist Pharms ENTEREG alvimopan CAPSULE;ORAL 021775-001 May 20, 2008 AB RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial A METHOD TO ACCELERATE THE TIME TO GASTROINTESTINAL RECOVERY BY ADMINISTERING ABOUT 12 MG OF ALVIMOPAN TO THE PATIENT FROM ABOUT 30 TO 60 MINUTES PRIOR TO SURGERY ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 8,946,262

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO) 2005055953 ⤷  Free Forever Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
McKinsey
Dow
AstraZeneca
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.